Skip to main content
DVA logo

DVA · Davita Inc.

Track DVA — free
$173.00 -1.22 (-0.70%) At close · Nov 17
Market Cap
$10.88B
Shares
62.90M
Volume · Nov 17 461.54K Avg daily vol (3M) 711.81K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$173.00 Open$174.00 Day$172.78–176.69 52W close$103.87–240.96 Avg vol 30d783K Short int5.1M · 8.2% of shares · 5.1d Short vol80% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Feb 1, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 10
Investor event
Q4 treatment decline expected, offset by RPT and IKC

DeVita expects a sequential Q4 treatment-volume decline, with higher RPT and a significant IKC step-up partly offsetting the impact.

4 source passages
So, treatment's down somewhat materially, Q3 to Q4. you've got the pieces right, and I think it highlights that seasonality is not the easiest dynamic to unpack at DeVita for a whole variety of reasons. So what we would expect is RPT to be up in Q4 over Q3 this year, but actually down in Q4 versus Q4 of last year, because Q4 of last year was so exaggerated. And IKC, you're absolutely right, and that's always been a tough one to pick up quarter by quarter, but we expect a big step up. Open the document at this passage
Nov 9
Investor event
2027 headwinds tempered by volume and pharmaceutical savings

DeVita expects a $70 million exchange headwind in 2027, while projecting positive volume growth and larger pharmaceutical cost savings; it estimates the full-year Medicare increase at 1.5% to 2%.

5 source passages
We're very pleased to have DeVita with us today. We're more than a year now at about a $70 million headwind for next year. This year, we're solidly positive, and we feel good about that, and we think next year will be another positive year, even better than this year. The cost savings opportunities on pharma are bigger than normal in 2027, and we think that will help mitigate some of the mixed pressure. We think 1.5% to 2% is a reasonable estimate for the full year. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly operating income falls to $499 million after China impairment

DaVita reported third-quarter 2026 operating income of $499 million, down from $579 million in the second quarter, while total consolidated revenues rose to $3,578 million from $3,554 million. The quarter included a $62 million goodwill and other asset impairment charge for its China business, and ancillary services posted a $19 million operating loss. Adjusted operating income was $561 million, down 3.1%.

Revenue $3.58B ▲ 4.6% Net income $222.93M ▲ 48.3% Diluted EPS $3.40 ▲ 66.7%
Read from the MD&A section
5 source passages
Operating income | 499 | 579 | (80) | (13.8)% Total consolidated revenues | 3,578 | 3,554 | 24 | 0.7% During the third quarter of 2026, we recognized goodwill and other asset impairment charges of $62 million related to our business in China. Total ancillary services operating income | (19) | 57 | (76) | (133.3)% Adjusted operating income | 561 | 579 | (18) | (3.1)% Open the document at this passage
Oct 29
Current report 8-K
Financial results

DaVita Inc. reported $3.578 billion in revenue, $3.40 diluted earnings per share and $519 million in operating cash flow for the quarter ended September 30, 2026. It recognized a $62 million impairment charge for its China business, resulting in a $27 million net income impact.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$14.17B
Trailing 12 months
Net income (TTM)
$920.08M
Trailing 12 months
Revenue growth YoY
+4.6%
Year over year
Operating margin
15.0%
Trailing 12 months
P / E (TTM)
12.8
Trailing earnings · reciprocal yield 7.8%
FCF yield
11.9%
TTM · current market cap
Return on invested capital
17.4%
Trailing 12 months
Net cash
−$10.20B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-11.2%
Year over year · fewer shares
Price change (1Y)
+47.5%
Trailing year
Short interest
8.2%
Latest settlement · 5.1 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. DaVita reaffirmed full-year 2026 adjusted operating income guidance (midpoint $2.2 billion) and adjusted EPS guidance (midpoint $14.65), raised its 2026 treatment volume outlook to the top end of its prior 25–50 bps range, and plans to deploy new expanded HD (middle molecule clearance) dialyzers across its network supported by sustained mortality improvement, though revenue per treatment and commercial mix face headwinds from ACA subsidy expiration.

Bullish
  • + Reaffirmed full-year 2026 adjusted operating income guidance with $2.2 billion midpoint and adjusted EPS midpoint of $14.65
  • + Raised 2026 total treatment volume outlook to near the top end of prior 25–50 bps guidance range
  • + Plans broad deployment of expanded HD (middle molecule clearance) dialyzers supported by secured supply and MOTHER trial non-inferiority results
  • + Sustained mortality improvement is driving volume growth and supporting return to at least 2% treatment volume growth by 2029
  • + Q2 adjusted operating income was $579 million with EPS of $4.02 and free cash flow of $256 million
  • + Phosphate binder transition cut reliance on less effective over-the-counter options like Tums by more than 50%, expanding access to clinically prepared therapies
Bearish
  • − Revenue per treatment declined approximately $2 sequentially due to lower commercial mix and reduced phosphate binder revenue
  • − Back-half 2026 revenue per treatment growth expected to be slightly negative year-over-year
  • − Year-to-date patient care costs per treatment have grown more than 3%, above the expected full-year range
  • − U.S. dialysis G&A grew roughly 10% in the quarter, pressuring operating leverage
  • − CMS 2027 ESRD proposed rule base rate update again tracks below industry cost trends, and final rule impact for 2027 remains uncertain
  • − Fewer admits from closed Fresenius clinics cut expected volume pickup by about five basis points year-to-date

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg −5%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 50%
mid-range
Momentum
relative strength
Weak
1-month return −1%
trailing
6-month return −12%
trailing
YTD return +52%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $182 › 200d $182 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +86 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.17% of shares out · ▲ +4.8% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
630 holders — near 3-yr high, broad support
Squeeze score 73
high risk · 0–100
Fundamentals
Strong
Revenue growth +6%
Y/Y
EPS growth −8%
Y/Y
Free cash flow $1.3B
Valuation P/E 12.8
below peers
Buyback $1.2B
remaining
Balance sheet $9.6B
net debt
Quant / Vol
risk profile
High
Volatility 47%
annualized · 1-yr
Max drawdown −28%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 29, 2026
Adjusted diluted net income per share attributable to DaVita Inc · Current 2026 guidance Non-GAAP $14.30 – $15.20
Previous outlook earlier release · from the 8-K filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted diluted net income per share attributable to DaVita Inc · 2026 $14.10 – $15.20
Guided vs delivered · last 1 settled
Revenue 2020
guided $11.5B – $11.7B
$11.55B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Neutral
Price vs 50-day avg
−5% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
50% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $182 › 200d $182 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +86 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.17% of shares out · ▲ +4.8% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
630 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $104 Now $173 · 50% Range high $241
vs 200-day avg -5% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Acquisition expenditures $5M three months ended June 30, 2026 —
Adjusted diluted per share non-GAAP $4.02 Three months ended June 30, 2026 —
Adjusted net income attributable to DaVita Inc. non-GAAP $265M three months ended June 30, 2026 —
Adjusted operating income non-GAAP $579M Three months ended June 30, 2026 —
Amount spent on share repurchases $348M three months ended June 30, 2026 —
Annualized aggregate risk based spend $5.8B June 30, 2026 —
Annualized medical spend for risk-based integrated care patients $5.8B As of June 30, 2026 —
Average patient service revenue per treatment $415.87 three months ended June 30, 2026 —
Average price paid per share repurchased $154.95 During the three months ended June 30, 2026 —
Average treatments per normalized day 92,649 the three months ended June 30, 2026 filing —
Average U.S. dialysis treatments per day 92,649 second quarter of 2026 —
Consolidated EBITDA non-GAAP $3.02B twelve months ended June 30, 2026 —
Depreciation and amortization expense per treatment $20.26 three months ended June 30, 2026 —
Development capital expenditures $47M three months ended June 30, 2026 —
Effective income tax rate on income attributable to DaVita Inc. non-GAAP 25.6% the three months ended June 30, 2026 filing —
Free cash flow non-GAAP $396M six months ended June 30, 2026 —
Free cash flow, last twelve months non-GAAP $1.31B twelve months ended June 30, 2026 —
General and administrative expenses per treatment $45.79 three months ended June 30, 2026 —
Maintenance capital expenditures $123M three months ended June 30, 2026 —
Normalized non-acquired treatment growth 0.3% second quarter of 2026 compared to the second quarter of 2025 —
Normalized treatment days 78 Q2 2026 —
Number of treatment days 78 three months ended June 30, 2026 —
Operating cash flow $490M Three months ended June 30, 2026 —
Operating cash flow, last twelve months $2.19B twelve months ended June 30, 2026 —
Operating margin 16.3% three months ended June 30, 2026 —
Other integrated care patients 5,700 June 30, 2026 —
Outpatient dialysis centers 3,266 As of June 30, 2026 —
Patient care costs per treatment $277.4 Three months ended June 30, 2026 —
Patients in risk-based integrated care arrangements 64,900 As of June 30, 2026 —
Patients receiving dialysis services 298,500 As of June 30, 2026 —
Per day year-over-year change 0.6% three months ended June 30, 2026 —
Per normalized day year-over-year change 0.6% three months ended June 30, 2026 —
Revenue per treatment $415.87 Three months ended June 30, 2026 —
Shares repurchased 2.2M During the three months ended June 30, 2026 —
Total debt $10.85B June 30, 2026 —
Total number of shares purchased 2.24M the three months ended June 30, 2026 filing —
Total U.S. dialysis treatments 7,226,600 second quarter of 2026 —
Treatments 7,226,600 three months ended June 30, 2026 —
Weighted average effective interest rate at end of the quarter 5.43% June 30, 2026 —
Weighted average effective interest rate on its senior secured credit facilities 5.76% end of the second quarter of 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DVA
Davita Inc.
this stock
$10.88B +52.3% +6.5% 12.8 8.2%
HCA
HCA Healthcare, Inc.
$104.69B +7.4% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.30B +3.1% — — 0.0%
THC
Tenet Healthcare Corp
$22.45B +41.9% +0.9% 8.2 2.2%
EHC
Encompass Health Corp
$13.53B +29.9% +10.5% 21.5 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
630
% held
95.7%
Net QoQ
+1.2M sh
Top holder
Berkshire Hathaway Inc
Held Float
View
Held by Funds
Fund positions
572
View
Short & Settlement
Short Interest Rising
Shares short
5.1M
Days to cover
5.1d
Change
+236.3K sh
View
Short Volume
Short vol %
80%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
651
Value
$118.3K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
36.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$13.6B
Net income (FY)
$746.8M
EPS diluted
$9.84
View
Buybacks
Authorized
$2.0B
Remaining
$1.2B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
14

DeVita expects a sequential Q4 treatment-volume decline, with higher RPT and a significant IKC step-up partly offsetting the impact.

View
Proposed Sales
Value
$8.2M
Shares
39.4K
Filed
Jun 16, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
DaVita Inc. to Participate in Upc…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
DVA -3.5% -1.3% -12.2% -7.7% +52.3%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -1.2% +3.4% -9.3% -4.7% +44.9%

Capital returns

Buyback program · as of Oct 27, 2026
Authorized
$2.00B
Spent (derived)
$787.58M
Remaining
$1.21B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 927066 CUSIP 23918K108 13F (30d) 637 filings 571 filers Visit website Investor relations